Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.
Adult
Antibodies, Monoclonal
/ pharmacology
Biomarkers
/ metabolism
Cross-Sectional Studies
Female
Flow Cytometry
Granzymes
/ metabolism
HTLV-I Infections
/ immunology
Humans
Interferon-gamma
/ metabolism
K562 Cells
Killer Cells, Natural
/ immunology
Male
Middle Aged
Natural Cytotoxicity Triggering Receptor 3
/ antagonists & inhibitors
Paraparesis, Tropical Spastic
/ immunology
Perforin
/ metabolism
CD107
HAM/TSP
HTLV-1
NK cells
NKp30
Natural cytotoxicity receptor
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
17 May 2019
17 May 2019
Historique:
received:
29
06
2018
accepted:
26
04
2019
entrez:
19
5
2019
pubmed:
19
5
2019
medline:
10
7
2019
Statut:
epublish
Résumé
Natural killer (NK) cells are part of the innate immune system and provide surveillance against viruses and cancers. The ability of NK cells to kill virus-infected cells depends on the balance between the effects of inhibitory and activating NK cell receptors. This study aimed to investigate the phenotypic profile and the functional capacity of NK cells in the context of HTLV-1 infection. This cross-sectional study sequentially recruited HTLV-1 infected individuals with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and asymptomatic HTLV-1 (AS) from the Integrated and Multidisciplinary HTLV Center in Salvador, Brazil. Blood samples from healthy blood donors served as controls. NK cell surface receptors (NKG2D, KIR2DL2/KIR2DL3, NKp30, NKG2A, NKp46, TIM-3 and PD-1), intracellular cytolytic (Granzyme B, perforin) and functional markers (CD107a for degranulation, IFN-γ) were assayed by flow cytometry in the presence or absence of standard K562 target cells. In addition, cytotoxicity assays were performed in the presence or absence of anti-NKp30. The frequency of NKp30 NK cells from individuals with a diagnosis of HAM/TSP present decreased expression of the activating receptor NKp30, in addition to elevated degranulation activity that remained unaffected after blocking the NKp30 receptor.
Sections du résumé
BACKGROUND
BACKGROUND
Natural killer (NK) cells are part of the innate immune system and provide surveillance against viruses and cancers. The ability of NK cells to kill virus-infected cells depends on the balance between the effects of inhibitory and activating NK cell receptors. This study aimed to investigate the phenotypic profile and the functional capacity of NK cells in the context of HTLV-1 infection.
METHODS
METHODS
This cross-sectional study sequentially recruited HTLV-1 infected individuals with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and asymptomatic HTLV-1 (AS) from the Integrated and Multidisciplinary HTLV Center in Salvador, Brazil. Blood samples from healthy blood donors served as controls. NK cell surface receptors (NKG2D, KIR2DL2/KIR2DL3, NKp30, NKG2A, NKp46, TIM-3 and PD-1), intracellular cytolytic (Granzyme B, perforin) and functional markers (CD107a for degranulation, IFN-γ) were assayed by flow cytometry in the presence or absence of standard K562 target cells. In addition, cytotoxicity assays were performed in the presence or absence of anti-NKp30.
RESULTS
RESULTS
The frequency of NKp30
CONCLUSIONS
CONCLUSIONS
NK cells from individuals with a diagnosis of HAM/TSP present decreased expression of the activating receptor NKp30, in addition to elevated degranulation activity that remained unaffected after blocking the NKp30 receptor.
Identifiants
pubmed: 31101076
doi: 10.1186/s12879-019-4032-1
pii: 10.1186/s12879-019-4032-1
pmc: PMC6525417
doi:
Substances chimiques
Antibodies, Monoclonal
0
Biomarkers
0
NCR3 protein, human
0
Natural Cytotoxicity Triggering Receptor 3
0
Perforin
126465-35-8
Interferon-gamma
82115-62-6
GZMB protein, human
EC 3.4.21.-
Granzymes
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
433Subventions
Organisme : Fundação de Amparo a Pesquisa do Estado da Bahia (FAPESB)
ID : 3373/2013
Références
J Neurovirol. 1998 Dec;4(6):586-93
pubmed: 10065900
Blood. 2000 Feb 15;95(4):1386-92
pubmed: 10666215
J Acquir Immune Defic Syndr. 2001 May 1;27(1):1-6
pubmed: 11404513
J Virol Methods. 2002 Apr;102(1-2):37-51
pubmed: 11879691
Blood. 2003 Jul 15;102(2):577-84
pubmed: 12560226
BMC Infect Dis. 2004 Mar 02;4:7
pubmed: 15070424
J Neurol Sci. 2005 Oct 15;237(1-2):53-9
pubmed: 15972218
Clin Vaccine Immunol. 2006 May;13(5):547-52
pubmed: 16682474
Clin Exp Immunol. 2006 Aug;145(2):296-301
pubmed: 16879249
AIDS Res Hum Retroviruses. 2006 Oct;22(10):931-5
pubmed: 17067261
Neuroimmunomodulation. 2006;13(3):145-51
pubmed: 17119343
J Neurol Sci. 1991 Sep;105(1):99-107
pubmed: 1795176
J Exp Med. 2009 Jul 6;206(7):1495-503
pubmed: 19528259
BMC Cancer. 2009 Jun 16;9:186
pubmed: 19531227
Braz J Med Biol Res. 2009 Aug;42(8):761-4
pubmed: 19578703
Lancet. 1990 Dec 1;336(8727):1345-7
pubmed: 1978165
Virulence. 2010 Jan-Feb;1(1):19-28
pubmed: 20640055
J Neuroimmunol. 1991 Aug;33(2):121-8
pubmed: 2066395
PLoS Pathog. 2010 Sep 23;6(9):e1001117
pubmed: 20886101
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Nat Med. 2011 Jun;17(6):700-7
pubmed: 21552268
J Med Virol. 2011 Jul;83(7):1269-74
pubmed: 21567429
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
J Clin Virol. 2011 Nov;52(3):177-80
pubmed: 21868282
PLoS Pathog. 2012 Jan;8(1):e1002480
pubmed: 22291590
AIDS Res Hum Retroviruses. 2013 Feb;29(2):359-64
pubmed: 22894552
Immunol Lett. 2013 Apr;152(1):16-24
pubmed: 23538009
Oncoimmunology. 2013 Mar 1;2(3):e23472
pubmed: 23802087
J Immunol. 2013 Sep 15;191(6):3308-18
pubmed: 23960237
PLoS Negl Trop Dis. 2013 Oct 10;7(10):e2479
pubmed: 24130912
Iran J Basic Med Sci. 2013 Mar;16(3):268-72
pubmed: 24470875
BMC Infect Dis. 2014 Aug 22;14:453
pubmed: 25148903
Sci Transl Med. 2015 Apr 15;7(283):283ra55
pubmed: 25877893
J Virol. 2015 Jul;89(13):6887-94
pubmed: 25903330
BMC Infect Dis. 2015 Jul 06;15:258
pubmed: 26143070
Oncotarget. 2015 Sep 8;6(26):21797-8
pubmed: 26392410
PLoS Negl Trop Dis. 2016 Mar 03;10(3):e0004499
pubmed: 26938618
Lancet. 1985 Aug 24;2(8452):407-10
pubmed: 2863442
J Immunol Res. 2019 Feb 28;2019:6574828
pubmed: 30944834
Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80
pubmed: 7031654
Virology. 1996 Dec 15;226(2):167-75
pubmed: 8955035